№ lp_1_2_04217
File format: docx
Character count: 93130
File size: 166 KB
This technical document provides a detailed prevalence model for peripheral arterial disease (PAD) in small populations, including statistical analyses and the methodology used to derive local prevalence estimates.
Year:
2015
Region / city:
United Kingdom
Topic:
Peripheral arterial disease, cardiovascular disease
Document type:
Technical Report
Organization / Institution:
Public Health England
Author(s):
Ben Hollis, Roger Newson, Bowen Su, Sarah Onida, Alun Davies, Azeem Majeed, Michael Soljak
Target audience:
Public health professionals, epidemiologists, healthcare researchers
Period of validity:
Not specified
Approval date:
Not specified
Date of last modification:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Author:
Martin Cowie, Saba Mian, Jessica Morris, Roger Newson, Michael Soljak, Bowen Su
Contextual description:
Technical document detailing heart failure prevalence modeling using UK primary care and hospital data, focusing on small populations.
Year:
2021
Region / City:
South Sudan
Topic:
Health service monitoring
Document Type:
Report
Organization / Institution:
World Bank
Author:
South Sudan health team, World Bank
Target Audience:
Stakeholders in South Sudan health sector
Period of Effectiveness:
2020-2021
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2025
Region / city:
Doncaster
Theme:
Religious Education
Document type:
Handbook
Organization / institution:
Pennine Learning Associates Ltd
Author:
Pennine Learning Associates Ltd
Target audience:
Teachers, Schools
Period of validity:
2025–2030
Approval date:
2025
Date of changes:
None
Note:
Year
Subject:
Food production and processing
Document type:
Educational guide
Target audience:
Pupils with additional needs
Context:
Educational material for understanding food production and processing for pupils with additional needs.
Year:
2026
Region:
Laboratory / Experimental Setting
Subject:
Plant growth under air pollution
Document type:
Scientific experiment report
Institution:
Not specified
Author:
Not specified
Target audience:
Researchers and students in plant biology and environmental science
Duration:
30 days
Variables studied:
Nitrogen dioxide, Sulfur dioxide
Results measurement:
Plant height in centimeters
Statistical analysis:
t-test
Year:
2013
Region / Country:
United States, Afghanistan, Central Asia, Pakistan, South Caucasus
Subject:
Defense acquisition regulations for operations in Afghanistan
Document type:
Class Deviation / Regulatory Guidance
Issuing authority:
Under Secretary of Defense for Acquisition, Technology, and Logistics
Target audience:
U.S. federal acquisition personnel and contractors
Legal reference:
Section 841, National Defense Authorization Act for Fiscal Year 2013 (Pub. L. 112-239)
Effective date:
January 29, 2013
Scope:
Acquisition of products and services (including construction) in support of U.S. operations in Afghanistan
Definitions included:
Products and services from Central Asia, Pakistan, South Caucasus; Central Asian states defined
Exemptions:
FAR Subpart 25.4 and Trade Agreements purchase restrictions for specified acquisitions
Procedures:
Acquisition procedures 225.7703-1(a), 225.7799-1(a) for support operations
Usage conditions:
Products/services must support U.S. or coalition forces, Afghan security forces, or supply routes to Afghanistan
Note:
Year
Subject:
Education, Environment, Science, Citizenship
Document Type:
Educational Standards
Target Audience:
Students, Teachers
Contextual Description:
A collection of educational standards for various topics, focusing on behavior, transportation, the environment, recycling, and food production aimed at guiding students in writing and understanding human interaction with nature and citizenship.
Year:
2024
Regulatory authority:
Therapeutic Goods Administration (TGA)
Medicine:
MACITENTAN 10 mg with TADALAFIL 40 mg (Opsynvi®)
Indication:
Pulmonary arterial hypertension (PAH), WHO Group 1, functional class II and III
Therapy type:
Dual or triple combination therapy
Dosage form:
Tablet, fixed dose combination (FDC)
Prescriber type:
Medical practitioners
Restriction type:
Authority Required (Written, Complex Authority Required)
Clinical criteria:
Treatment as dual therapy (MAC+TAD) or triple therapy with prostanoid
Population:
Adult patients with stable PAH on separate doses of macitentan and tadalafil
Previous considerations:
PBAC recommendations for macitentan and tadalafil since 2011–2014
Approval date:
16 September 2024
Source documents:
TGA registration, PBAC meeting minutes, ACM minutes August 2024, FDA, EMA, CDA references
Author:
General Practice Specification and Extraction Service (GPSES), NHS England
Publisher:
NHS England
Year:
2023–2024
Document type:
Business rules specification
Programme:
Quality and Outcomes Framework (QOF)
Clinical area:
Peripheral arterial disease
Version:
48.0–49.0
Version date:
01/04/2023–01/04/2024
Geographic scope:
England
Intended users:
GP system suppliers, NHS England, GP practices
Data source:
Primary Care systems
Clinical coding system:
SNOMED CT clinical reference sets
Indicators covered:
PAD001
Effective period:
QOF 2023/24 and 2024/25
Amendment history period:
2011–2024
Year:
Not specified
Region / City:
Not specified
Subject:
Arterial line insertion
Document type:
Competence assessment
Organization / Institution:
Not specified
Author:
Not specified
Target audience:
Healthcare practitioners (ANP / ACP / SCP)
Validity period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2019
Region / Country:
Australia
Subject:
Pulmonary arterial hypertension medicines and subsidy policy
Document Type:
Policy review agenda item and briefing
Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Program:
Pharmaceutical Benefits Scheme (PBS)
Topic:
Post-Market Review (PMR) of PAH medicines
Medicines Mentioned:
bosentan, ambrisentan, macitentan, sildenafil, tadalafil, iloprost, riociguat, epoprostenol
Medical Classification Referenced:
WHO Functional Class II–IV pulmonary arterial hypertension
Guidelines Referenced:
2015 European Society of Cardiology / European Respiratory Society Guidelines for the diagnosis and treatment of pulmonary hypertension
Stakeholders:
PAH Reference Group, medicine sponsors including Actelion, GlaxoSmithKline, and Pfizer
Regulatory Focus:
Revision of PBS prescribing restrictions and subsidy conditions
Key Policy Changes Considered:
Extension of subsidised monotherapy to WHO Functional Class II patients, updated PAH definition, inclusion of additional WHO Group 1 PAH subtypes, removal of calcium channel blocker trial requirement, strengthened diagnostic role of right heart catheterisation
Consultation Process:
Pre-PBAC consultation with sponsors and reference group
Associated Meetings:
PBAC meetings in November 2018, March 2019, and planned July 2019 review discussion
Related Policy Activity:
Planned stakeholder meeting on PAH combination therapy scheduled for May 2019
Year:
2020
Region / City:
United States
Subject:
Pulmonary Arterial Hypertension Treatment
Document Type:
Medical Appeal Letter
Institution / Organization:
Actelion Pharmaceuticals US, Inc.
Author:
Treating Physician (name to be inserted)
Patient:
[Insert patient name]
Patient Number:
[Insert Member Number]
Group Number:
[Insert Group Number]
Target Audience:
Medical Director, Insurance Company
Treatment:
OPSUMIT® (macitentan)
Medical Condition:
Pulmonary Arterial Hypertension (PAH, WHO Group I)
Supporting Documents:
Clinical peer-reviewed literature, Prescribing Information, test results
Note:
Year
Year:
2020
Region / City:
United States
Topic:
Pulmonary Arterial Hypertension Treatment
Document Type:
Medical Letter / Insurance Authorization Request
Organization:
Actelion Pharmaceuticals US, Inc.
Author:
Treating Physician [Insert Name]
Target Audience:
Insurance Medical Director
Patient:
[Insert Member Name]
Diagnosis:
Pulmonary Arterial Hypertension (PAH, WHO Group I)
Medication:
OPSUMIT® (macitentan)
Dose and Frequency:
[Insert Dose & Frequency]
Request Type:
Standard / Expedited
Supporting Documents:
Prescribing Information, Clinical Guidelines, Peer-reviewed Journal Articles
Documentation Recommendations to Assist with Adherence to the Peripheral Vestibular Hypofunction CPG
Year:
2023
Region / city:
N/A
Theme:
Vestibular rehabilitation
Document type:
Clinical guidelines
Author:
N/A
Target audience:
Healthcare professionals working with vestibular dysfunction
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Author:
General Practice Specification and Extraction Service (GPSES), NHS England
Publisher:
NHS England
Year:
2023–2024
Document type:
Business rules specification
Programme:
Quality and Outcomes Framework (QOF)
Clinical area:
Peripheral arterial disease
Version:
48.0–49.0
Version date:
01/04/2023–01/04/2024
Geographic scope:
England
Intended users:
GP system suppliers, NHS England, GP practices
Data source:
Primary Care systems
Clinical coding system:
SNOMED CT clinical reference sets
Indicators covered:
PAD001
Effective period:
QOF 2023/24 and 2024/25
Amendment history period:
2011–2024
Note:
Department
NHS boards should decide how to implement this bundle including:
when to complete it, how often it is completed, who completes it, where the data are collected and how results are fed back.
Year:
2026
Region / city:
Canberra
Topic:
Clinical Procedures, Healthcare, Intravenous Access
Document Type:
Procedure
Organization / institution:
Canberra Health Services
Author:
Not specified
Target audience:
Healthcare professionals at Canberra Health Services
Effective period:
Ongoing
Approval date:
Not specified
Revision date:
Not specified
Year:
2020
Topic:
Central Venous Access Devices
Type:
Skills Checklist
Author:
ATI Testing
Target Audience:
Healthcare Professionals
Procedure:
Dressing Change
Procedure Steps:
34
Date of Approval:
2020